Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Acrivon Therapeutics Inc. (ACRV) Insider Trading Activity
Healthcare • Biotechnology • 58 employees
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.
Total Value
-$954,218.82
Total Shares
-142,928
Average Trade Value
-$50,222.04
Most Active Insider
Blume Jensen Peter
Total Activity: $920,218
Largest Single Transaction
$473,347
by Blume Jensen Peter on Nov 14, 2024
30-Day Activity
8 Transactions
Volume: 59,595 shares
Value: $325,393
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
---|---|---|---|---|---|---|
President and CEO
|
Feb 21, 2025 | 19,904 | $110,268 | 2,285,781 (-0.9%) | Payment of Exercise Price | |
Chief Accounting Officer
|
Feb 14, 2025 | 116 | $629 | 4,419 (-2.6%) | Payment of Exercise Price | |
President and CEO
|
Feb 14, 2025 | 579 | $3,138 | 316,177 (-0.2%) | Payment of Exercise Price | |
President and CEO
|
Feb 14, 2025 | 37,152 | $201,364 | 2,305,685 (-1.6%) | Payment of Exercise Price | |
Chief Legal Officer
|
Feb 14, 2025 | 217 | $1,176 | 37,065 (-0.6%) | Payment of Exercise Price | |
Chief Development Officer
|
Feb 14, 2025 | 469 | $2,542 | 16,492 (-2.8%) | Payment of Exercise Price | |
Chief Financial Officer
|
Feb 14, 2025 | 434 | $2,352 | 26,088 (-1.7%) | Payment of Exercise Price | |
Chief Operating Officer
|
Feb 14, 2025 | 724 | $3,924 | 67,147 (-1.1%) | Payment of Exercise Price | |
Chief Legal Officer
|
Jan 17, 2025 | 659 | $3,809 | 37,282 (-1.8%) | Payment of Exercise Price | |
President and CEO
|
Nov 21, 2024 | 19,910 | $128,220 | 2,342,837 (-0.8%) | Payment of Exercise Price | |
President and CEO
|
Nov 14, 2024 | 490 | $3,881 | 316,756 (-0.2%) | Payment of Exercise Price | |
Chief Accounting Officer
|
Nov 14, 2024 | 99 | $784 | 4,535 (-2.2%) | Payment of Exercise Price | |
Chief Financial Officer
|
Nov 14, 2024 | 368 | $2,915 | 26,522 (-1.4%) | Payment of Exercise Price | |
Chief Operating Officer
|
Nov 14, 2024 | 613 | $4,855 | 67,871 (-0.9%) | Payment of Exercise Price | |
Chief Development Officer
|
Nov 14, 2024 | 402 | $3,184 | 16,961 (-2.4%) | Payment of Exercise Price | |
President and CEO
|
Nov 14, 2024 | 59,766 | $473,347 | 2,362,747 (-2.5%) | Payment of Exercise Price | |
Chief Legal Officer
|
Nov 14, 2024 | 184 | $1,457 | 37,941 (-0.5%) | Payment of Exercise Price | |
Chief Legal Officer
|
Oct 17, 2024 | 558 | $4,391 | 38,125 (-1.5%) | Payment of Exercise Price | |
Chief Legal Officer
|
Oct 1, 2024 | 284 | $1,982 | 38,683 (-0.7%) | Payment of Exercise Price |